Develop, optimize, and characterize robust human 3D organoid/spheroid models, including multicellular co-culture systems, for disease modelling and therapeutic efficacy applications spanning metabolic, fibrotic, inflammatory, and toxicological indications.
Perform advanced mammalian cell culture, including primary cells, stem cells, and co-culture systems, with multicellular organoid assembly experience preferred, maintaining strong experimental rigor and reproducibility throughout.
Design and standardize reproducible protocols for 3D organoid model generation, maintenance, maturation, differentiation, cryopreservation, recovery, and quality control, demonstrating strong command of tissue engineering principles.
Design, execute, and optimize functional assays evaluating viability, metabolism, DMPK studies, tissue-specific function, biomarker expression, and therapeutic response.
Working proficiency in techniques such as RT-qPCR, ELISA, Western blotting, ICC, IF, and flow cytometry, along with histology pipelines for tissue characterization, is required.
Expertise in fluorescence and confocal microscopy with quantitative image analysis to characterize structural and functional readouts of 3D organoid models; exposure to high-content imaging and automated image analysis is a plus.
Design experiments independently, analyze complex biological datasets, and interpret results, with solid grounding in experimental design, statistical analysis, and scientific data interpretation. Ability to prepare publication-quality figures, technical reports, and presentations is essential.
Contribute to mechanism-of-action studies by integrating molecular, functional, and phenotypic datasets, and develop, optimize, and validate novel assays and workflows that enhance the reproducibility, throughput, and translational relevance of organoid-based models; experience in biomarker identification, selection, and validation is preferred
Maintain comprehensive scientific documentation, including lab notebooks, SOPs, protocols, and validation reports, in compliance with internal quality systems.
Support scientific publications, IP generation, grant proposals, and external collaborations through data generation, analysis, and scientific writing; publication or patent experience is a plus.
Collaborate effectively across biology, bioengineering, translational research, computational biology, and process development to drive project objectives, with strong communication, presentation, and interpersonal skills to thrive in a fast-paced, multidisciplinary research environment.
Qualifications and Experience
PhD in a relevant discipline with 0-2 years of postdoctoral and/or industry research experience in Liver and Lung Organoids; OR
Master’s degree with 4+ years relevant research experience in Cell Biology, Molecular Biology, Biotechnology, Biochemistry, Regenerative Medicine, Tissue Engineering, Biomedical Sciences, or a related discipline
Ovii Interpretation
This Associate Research Scientist role develops and evaluates human 3D organoid and spheroid models for disease research and therapeutic efficacy studies. The work combines mammalian cell culture, tissue characterization, functional assays, quantitative imaging, and interpretation of biological data, with collaboration across research disciplines.
Role at a glance
3D organoid researchDisease modelingMammalian cell cultureFunctional assay developmentQuantitative microscopyExperimental design
Build, optimize, and characterize human 3D organoid and spheroid models, including multicellular co-cultures, for disease and therapeutic studies.
Culture primary cells and stem cells, and establish reproducible processes for organoid generation, maturation, differentiation, storage, and recovery.
Develop and run assays for viability, metabolism, DMPK, tissue-specific function, biomarkers, and treatment response.
Use molecular biology, immunostaining, flow cytometry, histology, and microscopy methods to characterize models and their responses.
Plan experiments, analyze biological datasets, interpret results, and prepare figures, reports, and presentations.
Integrate molecular, functional, and phenotypic results in mechanism-of-action studies and improve assay workflows.
Maintain lab notebooks, protocols, SOPs, and validation records; contribute data and writing to publications, IP, and proposals.
Work with biology, bioengineering, translational research, computational biology, and process development collaborators.
Good fit signals
Relevant doctoral training with 0–2 years of postdoctoral or industry research, or a relevant master’s degree with at least 4 years of research experience.
Research experience with liver and lung organoids is specified; multicellular organoid assembly experience is preferred.
Working proficiency in RT-qPCR, ELISA, Western blotting, ICC, IF, flow cytometry, and histology is required.
Strong fluorescence and confocal microscopy skills with quantitative image analysis are central to model characterization.
Experience in biomarker validation, publication or patent work, or high-content imaging can be helpful but is not stated as mandatory.
Meet Pandorum
Pandorum Technologies is a Bengaluru-based biotechnology company developing programmable regenerative medicines and engineered human tissues. Founded in 2011, its platform combines biomaterials, cellular engineering, designer exosomes and biofabrication to promote tissue repair and regeneration. Its lead therapeutic, Kuragenx, is a cell-free exosome-based treatment for severe corneal diseases and has received US FDA Orphan Drug Designation. Pandorum also develops 3D human liver organoids for drug research and regenerative approaches for lung and other tissues. The company operates R&D activities in India and the United States and collaborates with clinical and manufacturing partners including Northwestern Medicine, Medical University of South Carolina and Nucelion Therapeutics.
Founded
2011
Company size
11-50 employees
Company stage
Not known
Headquarters
Bengaluru, India
Why work here
Pandorum offers scientists and engineers the opportunity to work on clinical-stage regenerative medicine spanning designer exosomes, stem-cell biology, biomaterials, organoids and advanced biofabrication. Its lead therapy Kuragenx has received US FDA Orphan Drug Designation, and the company raised an $18 million Series B in 2026 to advance clinical development and global manufacturing. Pandorum also collaborates with clinical and manufacturing organizations in India and the US. Its careers page lists health and life insurance, family medical coverage, annual health checks, mental-health support and competitive compensation, while emphasizing continuous learning. Candidates should also consider the long validation, regulatory and clinical-development cycles inherent to biotechnology.
TBTuhin BhowmickCo-Founder, CEO and DirectorView bioHide bio
Co-founder, CEO and Director. Bhowmick holds a PhD from the Indian Institute of Science and completed postdoctoral research at the European Molecular Biology Laboratory as an EMBO-Marie Curie fellow. His expertise includes biophysics, biomaterials, structural biology, protein biochemistry and computational biology.
ACArun ChandruCo-Founder, CTO and DirectorView bioHide bio
Co-founder, CTO and Director. Chandru completed research in Aerospace Engineering at the Indian Institute of Science, where he received a gold medal for best thesis. His expertise spans systems engineering, advanced manufacturing and biofabrication. He was named to Forbes Asia's 30 Under 30 Healthcare & Science list in 2016.
SRSridhar RanganathanSenior Advisor - Commercialization and Strategic PartnershipsView bioHide bio
Advises Pandorum on commercialization and strategic partnerships. Ranganathan has more than three decades of healthcare experience and previously served as Managing Director of Allergan India and Associate Vice President at Allergan International, with expertise in ophthalmology, medical devices and healthcare commercialization.
Pandorum and Nucelion manufacturing partnership to advance two designer-exosome programmes in ophthalmology
BioSpectrum India·
Pandorum and Bharat Biotech subsidiary Nucelion Therapeutics expanded their manufacturing partnership to support two PRIP-backed ophthalmology programs targeting advanced keratopathy and wet age-related macular degeneration. The programs use Pandorum's designer-exosome regenerative-medicine platform.
Pandorum Technologies raises $18 million in Series B to scale tissue regenerative therapies
ET Pharma·
Pandorum closed an $18 million Series B round to advance clinical development of Kuragenx and other tunable exosome-based therapies, expand manufacturing capacity and grow operations across the United States, Japan and the Middle East.
Pandorum Technologies and Nucelion Therapeutics announce strategic manufacturing collaboration for ocular regenerative therapies
Business Wire·
Pandorum partnered with Nucelion Therapeutics to build manufacturing capabilities for its exosome-based ocular regenerative therapies across Asia-Pacific, supporting clinical development, regional supply and regulatory readiness.